Squarepoint
TARS icon

Squarepoint’s Tarsus Pharmaceuticals TARS Stock Holding History

Squarepoint’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.6M Buy
295,824
+54,791
+23% +$3.5M 0.02% 724
2026
Q1 		$16.9M Buy
241,033
+219,200
+1,004% +$15.3M 0.02% 792
2025
Q4 		$1.79M Sell
21,833
-59,646
-73% -$4.45M ﹤0.01% 2143
2025
Q3 		$4.84M Sell
81,479
-21,163
-21% -$1.04M ﹤0.01% 1495
2025
Q2 		$4.16M Buy
102,642
+44,986
+78% +$2.02M ﹤0.01% 1576
2025
Q1 		$2.96M Buy
57,656
+51,652
+860% +$2.55M ﹤0.01% 1793
2024
Q4 		$332K Sell
6,004
-51,329
-90% -$2.33M ﹤0.01% 4077
2024
Q3 		$1.89M Buy
+57,333
New +$1.61M ﹤0.01% 2115
2024
Q2 		– Sell
-33,867
Closed -$1.23M – 4640
2024
Q1 		$1.23M Buy
+33,867
New +$996K ﹤0.01% 2436
2023
Q4 		– Sell
-19,344
Closed -$344K – 4497
2023
Q3 		$344K Buy
19,344
+9,303
+93% +$165K ﹤0.01% 3067
2023
Q2 		$181K Sell
10,041
-3,896
-28% -$61.9K ﹤0.01% 3252
2023
Q1 		$175K Buy
+13,937
New +$204K ﹤0.01% 2851

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Squarepoint's TARS Position: Q2 2026 in Review

Squarepoint increased its Tarsus Pharmaceuticals (TARS) stake by 23% in Q2 2026, buying an estimated $3.5M and bringing the position to 295,824 shares worth $18.6M. The position accounts for 0.02% of the portfolio, ranked #724.

Squarepoint first reported a position in TARS in Q1 2023 and has held it in 12 quarters since. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Squarepoint held 295,824 shares of Tarsus Pharmaceuticals worth $18.6M as of Q2 2026.
  • Squarepoint bought 54,791 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $3.5M.
  • Tarsus Pharmaceuticals made up 0.02% of Squarepoint's portfolio in Q2 2026, its #724 holding.
  • Squarepoint first reported a position in Tarsus Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.